These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21796614)

  • 41. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
    Swarbrick A; Woods SL; Shaw A; Balakrishnan A; Phua Y; Nguyen A; Chanthery Y; Lim L; Ashton LJ; Judson RL; Huskey N; Blelloch R; Haber M; Norris MD; Lengyel P; Hackett CS; Preiss T; Chetcuti A; Sullivan CS; Marcusson EG; Weiss W; L'Etoile N; Goga A
    Nat Med; 2010 Oct; 16(10):1134-40. PubMed ID: 20871609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cell cycle regulation targets of MYCN identified by gene expression microarrays.
    Bell E; Lunec J; Tweddle DA
    Cell Cycle; 2007 May; 6(10):1249-56. PubMed ID: 17495526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
    Liu HJ; Li GL; Lei PC
    Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
    [No Abstract]   [Full Text] [Related]  

  • 45. Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.
    Zhang H; Liu T; Yi S; Gu L; Zhou M
    Mol Oncol; 2015 Aug; 9(7):1301-11. PubMed ID: 25864587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.
    Mestdagh P; Fredlund E; Pattyn F; Schulte JH; Muth D; Vermeulen J; Kumps C; Schlierf S; De Preter K; Van Roy N; Noguera R; Laureys G; Schramm A; Eggert A; Westermann F; Speleman F; Vandesompele J
    Oncogene; 2010 Mar; 29(9):1394-404. PubMed ID: 19946337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.
    Samaraweera L; Spengler BA; Ross RA
    Oncol Rep; 2017 Jul; 38(1):545-550. PubMed ID: 28560387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
    Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
    Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
    Lodrini M; Oehme I; Schroeder C; Milde T; Schier MC; Kopp-Schneider A; Schulte JH; Fischer M; De Preter K; Pattyn F; Castoldi M; Muckenthaler MU; Kulozik AE; Westermann F; Witt O; Deubzer HE
    Nucleic Acids Res; 2013 Jul; 41(12):6018-33. PubMed ID: 23625969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
    Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Terada K; Itadani M; Okada N; Hassan NMM; Nagatsuka H; Ikeda T; Nohno T; Fujita S
    Oncol Res; 2018 Jan; 26(1):45-58. PubMed ID: 28470144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
    Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
    Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells.
    Lodrini M; Poschmann G; Schmidt V; Wünschel J; Dreidax D; Witt O; Höfer T; Meyer HE; Stühler K; Eggert A; Deubzer HE
    J Proteome Res; 2016 Jul; 15(7):2178-86. PubMed ID: 27239679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MYC Hyperactivates Wnt Signaling in
    Sehgal P; Lanauze C; Wang X; Hayer KE; Torres-Diz M; Leu NA; Sela Y; Stanger BZ; Lengner CJ; Thomas-Tikhonenko A
    Mol Cancer Res; 2021 Dec; 19(12):2003-2014. PubMed ID: 34593610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
    J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MiR-92a modulates proliferation, apoptosis, migration, and invasion of osteosarcoma cell lines by targeting Dickkopf-related protein 3.
    Yu H; Song H; Liu L; Hu S; Liao Y; Li G; Xiao X; Chen X; He S
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30926679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microarray data analysis of neuroblastoma: Expression of SOX2 downregulates the expression of MYCN.
    Bao J; Qin L; Cui L; Wang X; Meng Q; Zhu L; Zhang S
    Mol Med Rep; 2015 Nov; 12(5):6867-72. PubMed ID: 26398570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.